Comprehensive medication guide to Invega including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay for generic paliperidone ER on commercial plans (Tier 2–3); brand Invega typically Tier 4 on Medicare Part D with higher cost-sharing. Prior authorization required for injectable formulations. Janssen CarePath can reduce commercially insured patients' cost to as little as $10/dose for Invega Sustenna.
Estimated Cash Pricing
$680–$684 retail for brand Invega oral tablets (30-day supply); as low as $32–$36 with GoodRx or SingleCare coupons for generic paliperidone ER. Injectable forms (Invega Sustenna) are specialty medications billed through insurance.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Invega is the brand name for paliperidone, an atypical (second-generation) antipsychotic manufactured by Janssen Pharmaceuticals (Johnson & Johnson). Paliperidone is the primary active metabolite of risperidone — it's the chemical form that risperidone converts to in the body. Invega delivers paliperidone directly using OROS extended-release technology, allowing once-daily dosing without the variability of hepatic metabolism.
Invega was first FDA-approved in December 2006 for schizophrenia in adults, and subsequently approved for schizoaffective disorder (2009). It is also FDA-approved for schizophrenia in adolescents ages 12–17. Generic paliperidone extended-release is available and FDA-approved as therapeutically equivalent to brand Invega tablets. Injectable forms — Invega Sustenna (monthly), Invega Trinza (quarterly), and Invega Hafyera (every 6 months) — remain brand-only.
Paliperidone is listed on the World Health Organization's List of Essential Medicines and is considered a foundational treatment for psychotic disorders globally.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Invega works primarily by blocking dopamine D2 receptors and serotonin 5-HT2A receptors in the brain. By reducing excessive dopamine signaling in the limbic system, paliperidone alleviates positive symptoms of schizophrenia such as hallucinations and delusions. The 5-HT2A blockade helps modulate dopamine release in the prefrontal cortex, which may improve negative symptoms and reduce the risk of extrapyramidal side effects compared to older antipsychotics.
Paliperidone also blocks alpha-1 and alpha-2 adrenergic receptors (contributing to orthostatic hypotension) and histamine H1 receptors (contributing to sedation). Notably, it has minimal anticholinergic activity, which distinguishes it from some other antipsychotics and results in fewer dry mouth, constipation, and urinary retention effects. Because paliperidone is primarily renally excreted (~59% unchanged), it is minimally affected by liver metabolism — an advantage for patients with hepatic impairment or CYP2D6 variations.
The oral OROS tablet delivers paliperidone at a controlled rate over 24 hours using osmotic pressure technology. The long-acting injectables (Sustenna, Trinza, Hafyera) use paliperidone palmitate, a fatty acid ester that forms a depot after intramuscular injection and slowly releases paliperidone over weeks to months.
1.5 mg — extended-release tablet
Lowest oral dose; typically used for renal impairment
3 mg — extended-release tablet
Starting dose for adolescents 12-17; low-end adult dose for renal impairment
6 mg — extended-release tablet
Standard adult starting dose for schizophrenia and schizoaffective disorder
9 mg — extended-release tablet
Intermediate dose for patients needing more than 6 mg
12 mg — extended-release tablet
Maximum daily oral dose
39–234 mg — injectable suspension (Invega Sustenna)
Monthly LAI; 234 mg loading dose day 1, 156 mg day 8, then maintenance 117 mg monthly
273–819 mg — injectable suspension (Invega Trinza)
Quarterly LAI; for patients stable on Sustenna ≥4 months
1092–1560 mg — injectable suspension (Invega Hafyera)
Every-6-month LAI; for patients stable on Sustenna or Trinza
Oral generic paliperidone ER is generally available at most retail pharmacies and is not on the FDA's active drug shortage list as of 2026. However, availability can vary by location, pharmacy, and dose strength — particularly the less common strengths (1.5 mg, 9 mg, 12 mg). Brand-name Invega tablets are less commonly stocked since most pharmacies substitute the generic automatically.
The injectable forms — Invega Sustenna, Trinza, and Hafyera — are brand-only specialty medications distributed through a limited network of specialty pharmacies and administered in clinical settings. They are not available at standard retail pharmacy counters and require prior insurance authorization (typically 2–4 weeks). Patients in rural areas may face additional logistical challenges accessing injection appointments.
If you're having trouble filling your Invega prescription, medfinder calls pharmacies near you to check who has your specific medication in stock and texts you the results — saving you hours of calls.
Invega (paliperidone) is not a controlled substance, so there are no DEA scheduling restrictions on who can prescribe it. Any licensed prescriber with authority to prescribe medications in their state can prescribe paliperidone. In clinical practice, it is most commonly prescribed by mental health specialists due to the nature of its indications.
Psychiatrists — Primary prescribers; specialize in schizophrenia and schizoaffective disorder diagnosis and management
Primary care physicians (PCPs) — May prescribe for established patients, especially in areas with limited psychiatrist access
Psychiatric nurse practitioners (PMHNPs) — Independent prescribers in most states; major source of outpatient psychiatric care
Physician assistants (PAs) — Can prescribe under supervision or independently depending on state law
Child and adolescent psychiatrists — For patients ages 12–17 with schizophrenia
Because paliperidone is not scheduled, it can be prescribed via telehealth in all 50 states without any additional DEA registration requirements. Telehealth psychiatric platforms such as Talkiatry, Teladoc, and Cerebral can initiate and manage paliperidone therapy for appropriate patients. Note that injectable formulations (Invega Sustenna, Trinza, Hafyera) still require in-person administration by a trained healthcare professional, even if the prescription was obtained via telehealth.
No. Invega (paliperidone) is not a controlled substance under U.S. federal law. It has no DEA schedule. This means any licensed prescriber — including physicians, nurse practitioners, and physician assistants — can prescribe it without special DEA registration or prescribing restrictions.
Because it is not scheduled, Invega can be prescribed via telehealth in all 50 states without additional regulatory requirements. Refills do not require a new in-person visit in the same way controlled substances do (though clinical monitoring appointments are still clinically recommended). This makes paliperidone more accessible than scheduled antipsychotics or controlled psychiatric medications.
Somnolence/drowsiness
Akathisia (restlessness/urge to move)
Extrapyramidal symptoms (tremors, muscle stiffness)
Weight gain
Hyperprolactinemia (elevated prolactin — sexual side effects, menstrual changes)
Tachycardia, dizziness, orthostatic hypotension
Headache, nausea, insomnia, anxiety
Serious side effects (require immediate medical attention):
Tardive dyskinesia (potentially permanent involuntary movements)
Neuroleptic malignant syndrome (NMS) — fever, rigidity, altered consciousness (emergency)
QT prolongation / cardiac arrhythmia
Metabolic changes: hyperglycemia, diabetes, dyslipidemia
Severe allergic reaction (especially in patients with risperidone allergy)
Know what you need? Skip the search.
Risperidone (Risperdal)
Parent compound of paliperidone; nearly identical mechanism; very affordable generic; approved for schizophrenia, bipolar disorder, and autism irritability
Aripiprazole (Abilify)
Partial D2 agonist; lower prolactin and weight gain; available as monthly LAI (Abilify Maintena); generic available
Quetiapine (Seroquel)
D2/5-HT2A antagonist; sedating; good for comorbid insomnia; low EPS risk; generic widely available
Olanzapine (Zyprexa)
Broad receptor profile; highly effective; significant metabolic/weight gain risk; generic available
Lurasidone (Latuda)
Favorable metabolic profile; must take with ≥350 calories; approved for schizophrenia and bipolar depression; generic available
Prefer Invega? We can find it.
Risperidone
majorConcurrent use doubles paliperidone exposure; significantly increases QT prolongation risk. Contraindicated — do not use together.
QT-prolonging drugs (antiarrhythmics, thioridazine, chlorpromazine, moxifloxacin, goserelin, leuprolide)
majorAdditive QT prolongation increasing risk of torsade de pointes. Many are contraindicated or require ECG monitoring.
Amisulpride
majorContraindicated — increases risk of neuroleptic malignant syndrome.
Carbamazepine (Tegretol)
moderateStrong CYP3A4/P-gp inducer; reduces paliperidone levels by ~37%. May need to increase paliperidone dose. Monitor on initiation/discontinuation.
Divalproex sodium (Depakote)
moderateIncreases paliperidone Cmax/AUC by ~50%. May need to reduce paliperidone dose. Monitor for increased side effects.
CNS depressants (benzodiazepines, opioids, alcohol, sleep aids)
moderateAdditive CNS depression — increased sedation, impaired coordination, respiratory depression risk.
Antihypertensives
moderateAdditive orthostatic hypotension. Monitor blood pressure; fall risk in elderly.
Levodopa / dopamine agonists
moderatePaliperidone may antagonize therapeutic effects of dopaminergic agents. Use with caution in Parkinson's disease patients.
St. John's Wort
moderateStrong P-gp and CYP3A4 inducer; reduces paliperidone blood levels, risking treatment failure. Avoid.
Fluoroquinolone antibiotics (moxifloxacin, levofloxacin)
moderateAdditional QT-prolonging effect. Choose alternative antibiotic class when possible.
Invega (paliperidone) is a well-established atypical antipsychotic that plays an important role in the management of schizophrenia and schizoaffective disorder. Its once-daily oral dosing, predictable pharmacokinetics due to minimal hepatic metabolism, and the availability of long-acting injectable formulations for adherence-challenged patients make it a versatile option in the psychiatric formulary.
For patients managing costs, generic paliperidone ER is an FDA-approved, therapeutically equivalent, and significantly more affordable alternative to brand-name Invega tablets. Manufacturer savings programs (Janssen CarePath) can reduce the cost of injectable formulations to as little as $10 per dose for eligible commercially insured patients. For uninsured patients, the J&J Patient Assistance Foundation may provide the medication at no charge.
If you're having difficulty finding Invega at your local pharmacy, medfinder can help — our service calls pharmacies near you to find which ones have your medication in stock and texts you the results, saving you hours of searching.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini